Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT).
Marabelle A, Andtbacka R, Harrington K, Melero I, Leidner R, de Baere T, Robert C, Ascierto PA, Baurain JF, Imperiale M, Rahimian S, Tersago D, Klumper E, Hendriks M, Kumar R, Stern M, Öhrling K, Massacesi C, Tchakov I, Tse A, Douillard JY, Tabernero J, Haanen J, Brody J. Marabelle A, et al. Among authors: rahimian s. Ann Oncol. 2018 Nov 1;29(11):2163-2174. doi: 10.1093/annonc/mdy423. Ann Oncol. 2018. PMID: 30295695 Free PMC article.
Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma.
Haymaker C, Johnson DH, Murthy R, Bentebibel SE, Uemura MI, Hudgens CW, Safa H, James M, Andtbacka RHI, Johnson DB, Shaheen M, Davies MA, Rahimian S, Chunduru SK, Milton DR, Tetzlaff MT, Overwijk WW, Hwu P, Gabrail N, Agrawal S, Doolittle G, Puzanov I, Markowitz J, Bernatchez C, Diab A. Haymaker C, et al. Among authors: rahimian s. Cancer Discov. 2021 Aug;11(8):1996-2013. doi: 10.1158/2159-8290.CD-20-1546. Epub 2021 Mar 11. Cancer Discov. 2021. PMID: 33707233 Free PMC article. Clinical Trial.
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101).
Babiker H, Borazanci E, Subbiah V, Agarwala S, Algazi A, Schachter J, Lotem M, Maurice-Dror C, Hendler D, Rahimian S, Minderman H, Haymaker C, Mahadevan D, Bernatchez C, Murthy R, Hultsch R, Kaplan N, Woodhead G, Hennemeyer C, Chunduru S, Anderson PM, Diab A, Puzanov I. Babiker H, et al. Among authors: rahimian s. Clin Cancer Res. 2022 Dec 1;28(23):5079-5087. doi: 10.1158/1078-0432.CCR-21-4486. Clin Cancer Res. 2022. PMID: 35917516 Free PMC article.
COVID-19 Coagulopathy.
Rettew A, Garrahy I, Rahimian S, Brown R, Sangha N. Rettew A, et al. Among authors: rahimian s. Life (Basel). 2024 Jul 29;14(8):953. doi: 10.3390/life14080953. Life (Basel). 2024. PMID: 39202695 Free PMC article. Review.
Salivary levels of disease-related biomarkers in the early stages of Parkinson's and Alzheimer's disease: A cross-sectional study.
Sabaei M, Rahimian S, Haj Mohamad Ebrahim Ketabforoush A, Rasoolijazi H, Zamani B, Hajiakhoundi F, Soleimani M, Shahidi G, Faramarzi M. Sabaei M, et al. Among authors: rahimian s. IBRO Neurosci Rep. 2023 Mar 8;14:285-292. doi: 10.1016/j.ibneur.2023.03.004. eCollection 2023 Jun. IBRO Neurosci Rep. 2023. PMID: 36942319 Free PMC article.
44 results